Research Analysts Offer Predictions for ESPR FY2024 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report issued on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will earn ($0.27) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.27) per share.

A number of other equities analysts also recently issued reports on the stock. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research note on Wednesday. They issued a “neutral” rating and a $4.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and an average target price of $7.30.

Esperion Therapeutics Stock Performance

ESPR stock opened at $2.17 on Thursday. The company has a market cap of $427.57 million, a price-to-earnings ratio of -3.39 and a beta of 1.01. The business’s 50-day moving average is $2.41 and its two-hundred day moving average is $2.22. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BOKF NA purchased a new stake in Esperion Therapeutics during the 2nd quarter valued at about $26,000. Xponance Inc. purchased a new position in Esperion Therapeutics in the second quarter worth approximately $28,000. Traphagen Investment Advisors LLC acquired a new stake in Esperion Therapeutics during the third quarter worth $27,000. National Bank of Canada FI raised its position in Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the period. Finally, Sivia Capital Partners LLC acquired a new position in shares of Esperion Therapeutics in the 2nd quarter valued at $44,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.